SOLIGENIX, INC. Stock Split Ratio
SOLIGENIX, INC. (SNGX) had Stock Split Ratio of 6.25% as of 2024-06-05, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-03-31
- 2024-06-05: Stockholders' Equity Note, Stock Split, Conversion Ratio 6.25%.
- 2023-02-10: Stockholders' Equity Note, Stock Split, Conversion Ratio 6.70%.
- 2023-02-09: Stockholders' Equity Note, Stock Split, Conversion Ratio 6.70%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2024-06-05 | 6.25% 10-K · filed 2026-03-31 |
| 2023-02-10 | 6.70% 10-Q · filed 2023-11-13 |
| 2023-02-09 | 6.70% 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |